Loading
Breast cancer specialist who leads Yale Cancer Center and Smilow Cancer Hospital, and who previously ran breast oncology at Dana-Farber for more than two decades.
Medical oncologist appointed Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital on 1 February 2022, after leading the breast oncology programme at Dana-Farber Cancer Institute, where he was Chief of the Division of Breast Oncology and Chief Clinical Strategy Officer. His research has focused on the treatment of breast cancer, in particular HER2-positive disease, de-escalation of therapy for lower-risk patients and the design of adjuvant and neoadjuvant trials through the Alliance cooperative group and Translational Breast Cancer Research Consortium. He served as President of the American Society of Clinical Oncology for 2022-2023.
| Title | Journal | Year |
|---|---|---|
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer | New England Journal of Medicine | 2015 |
| Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial | Lancet Oncology | 2021 |
The clearest demonstration that PD-L1 positive in triple-negative breast cancer means different things depending on the kit; with atezolizumab withdrawn, pembrolizumab's 22C3 combined positive score of 10 is the surviving standard, and roughly a quarter of patients get a different answer depending on which assay their laboratory runs.
TMB-high is uncommon but not negligible in TNBC, rises at relapse, and the tumour-agnostic pembrolizumab indication makes it worth measuring on a metastatic biopsy.
Enzalutamide works modestly in AR-positive TNBC and is the reference for the LAR subtype's therapy implication; the AR threshold used for eligibility changes who counts as positive.
Shares Yale Cancer Center / Smilow Cancer Hospital, Triple-negative breast cancer (TNBC), Pembrolizumab.
Shares Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer, PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer, Triple-negative breast cancer (TNBC), Pembrolizumab.
Shares Prevalence and mutational determinants of high tumor mutation burden in breast cancer, Dana-Farber Brigham Cancer Center, HER2-positive breast cancer.
Shares PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer, Triple-negative breast cancer (TNBC), Pembrolizumab.
Shares Yale Cancer Center / Smilow Cancer Hospital, Pembrolizumab.
Shares Yale Cancer Center / Smilow Cancer Hospital, HER2-positive breast cancer.
Shares Prevalence and mutational determinants of high tumor mutation burden in breast cancer, Dana-Farber Brigham Cancer Center, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).